Skip to main content

Day: January 22, 2020

Grapefruit/IGNG Announces Filing Amendment No. 1 to Registration Statement.

Los Angeles & Desert Hot Springs, California, Jan. 22, 2020 (GLOBE NEWSWIRE) — Grapefruit Boulevard Investments, Inc., (“GBI”) a licensed and fully compliant California based cannabis distribution and manufacturing company and a wholly owned subsidiary of Imaging3, Inc., a Delaware corporation (OTCQB: IGNG) (collectively “Grapefruit” or the “Company”) is announcing today that it filed Amendment No. 1 to its Registration Statement on Form S-1 originally filed on July 28, 2019. The Registration Statement covers shares to be issued to its institutional investor, Auctus Fund, LLC. (“Auctus”) of Boston, MA in connection with conversions of Convertible Notes (the “Notes”) issued to Auctus at 95% of Market and upon exercise of callable cash exercise only Warrants issued by...

Continue reading

Qutoutiao Inc. Announces Director and Management Change

SHANGHAI, China, Jan. 22, 2020 (GLOBE NEWSWIRE) — Qutoutiao Inc. (“Qutoutiao”, the “Company” or “We”) (NASDAQ: QTT), a leading operator of mobile content platforms in China, today announced a transition in the role of the Company’s Chief Financial Officer and a change in the Board.Mr. Jingbo Wang has resigned as a Director and Chief Financial Officer of the Company due to personal reasons. The resignation is effective on January 22, 2020. Following Mr. Wang’s resignation, the Board of the Company is now comprised of seven members. Mr. Wang’s duties of financial management will be assumed by Mr. Xiaolu Zhu, the current Co-Chief Financial Officer responsible for investor relations and capital markets related affairs of the Company.About Qutoutiao Inc.Qutoutiao Inc. operates innovative...

Continue reading

IBC Advanced Alloys Provides Litigation Update

FRANKLIN, Ind., Jan. 22, 2020 (GLOBE NEWSWIRE) — IBC Advanced Alloys Corp. (“IBC” or the “Company”) (TSX-V: IB; OTCQB: IAALF) announces that the United States Court of Appeals for the First Circuit affirmed the judgment of the United States District Court for the District of Massachusetts in the case of Gerald R. Hoolahan v. IBC Advanced Alloys Corp., which found in favor of the petitioner, Mr. Hoolahan.IBC will continue to evaluate all options available to the Company relating to the requirement to pay the arbitration award of approximately $1.4 million.  As has been disclosed in previous public filings, the Company has already reserved the full amount of the potential award as a liability on its books.For more information on IBC and its innovative alloy products, go here.On Behalf of the Board of Directors:“Mark...

Continue reading

Correction: MyBest Group S.p.A. : Ordinary shareholders’ meeting

                                              MYBEST GROUP S.P.A.Registered office in Sesto San Giovanni (MI), Viale Casiraghi 359 – 20099Share capital € 3.334.309,50 fully paidVAT 04227580968 – Tax code 04227580968Milan R.E.A. registration no. 1735084* * * * * * * * *Minutes of the ordinary shareholders’ meetingIn the year 2019, on the 18thof December, at 03:30pm, at the registered office of the company MY BEST GROUP spa, in Sesto San Giovanni 20099 (MI), Viale Fratelli Casiraghi 359, the shareholders’ meeting of the company MyBest Group S.p.A. was held, after a first call, to discuss and...

Continue reading

Impressive Results Continue from CytoDyn’s Clinical Trials Evaluating Two Patients with Leronlimab, One in mTNBC and One in MBC

First patient with metastatic triple-negative breast cancer (mTNBC) continues to show no detectable circulating tumor cells (CTC) or putative metastatic tumor cells after 15 weeks of treatment with leronlimab in combination with carboplatinSecond patient with stage 4 HER2+ metastatic breast cancer (MBC) shows 50 percent shrinkage in the primary tumor and no new signs of metastasis in the brain after treatment with leronlimab as a monotherapyVANCOUVER, Washington, Jan. 22, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today additional promising results from its clinical trials evaluating leronlimab for the treatment of...

Continue reading

Reporting dates in 2020

 Utenos trikotažas AB, informs that the group results in 2020 will be released till the following preliminary dates: –       Consolidated Interim Financial Statements for 12 months of 2019 – February 28; –       Audited Consolidated Financial Statements for the year 2019 – April 30; –       Consolidated Interim Financial Statements for 3 months of 2020 – April 30; –       Consolidated Interim Financial Statements for 6 months of 2020 – July 31; –       Consolidated Interim Financial Statements for 9 months of 2020 – October 30. For more information: AB “Utenos Trikotažas“ Managing Director Petras...

Continue reading

Preliminarios AB “Utenos trikotažas” veiklos rezultatų skelbimo 2020 metais datos

 AB „Utenos trikotažas“ praneša, kad 2020 metais įmonių grupės veiklos rezultatus planuoja skelbti tokia tvarka: –       vasario 28 d. – 2019 m. 12 mėnesių tarpinė konsoliduota finansinė atskaitomybė; –       balandžio 30 d. – audituota 2019 m. metinė konsoliduota finansinė atskaitomybė; –       balandžio 30 d. – 2020 m. 3 mėnesių tarpinė konsoliduota finansinė atskaitomybė; –       liepos 31 d. – 2020 m. 6 mėnesių tarpinė konsoliduota finansinė atskaitomybė; –       spalio 30 d. – 2020...

Continue reading

Form 8.5 (EPT/RI) – Sirius Minerals Plc

FORM 8.5 (EPT/RI)PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITYRule 8.5 of the Takeover Code (the “Code”)1.         KEY INFORMATION2.         DEALINGS BY THE EXEMPT PRINCIPAL TRADER(a)        Purchases and sales(b)        Derivatives transactions (other than options)(c)        Options transactions in respect of existing securities(i)         Writing, selling, purchasing or varying(ii)        Exercising(d)        Other dealings (including subscribing for new...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.